OCT Inhibitors

Chemical inhibitors of OCT can vary in structure and function, yet they commonly share the ability to interfere with the protein's role in the uptake of organic cations. Quinine, as an example, competes directly with the natural substrates of OCT for binding, which blocks the entry of these substrates into the cells. Similarly, Amantadine, though initially recognized for its antiviral effects, can also inhibit OCT by obstructing its ion channel-like function, preventing the transport of organic cations. Tetraethylammonium (TEA), another potassium channel blocker, competes for transport pathways that are critical for OCT function. This competitive inhibition is a recurring mechanism among various chemicals like Decynium-22 and Laetrile, which also bind to OCT, impeding the cellular uptake of its natural substrates.

Furthermore, Propranolol, a non-selective beta-blocker, and Disopyramide, a Class 1a antiarrhythmic agent, both inhibit OCT by vying for the cation transport pathway within the protein. This competitive binding not only prevents substrate translocation but also ensures that the inhibitor molecules occupy the transport site, reducing the efficiency of OCT. Corticosterone, while a steroid hormone, can indirectly inhibit OCT by modifying the membrane potential, which is indirectly critical for the function of OCT. Local anesthetics like Lidocaine inhibit OCT by a similar principle, blocking the ion channel-like activity crucial for OCT's transport capabilities. Some inhibitors, such as Mibefradil and Verapamil, although primarily known for their role as calcium channel blockers, also demonstrate inhibitory action against OCT by competing with organic cations for binding and transport. Lastly, Pyrilamine, an antihistamine, can inhibit OCT by occupying the binding sites that are typically reserved for organic cations, thereby blocking their cellular uptake and inhibiting the function of OCT.